As part of a £10.5 million investment to life sciences, BioClavis have announced they will be creating a base in the Queen Elizabeth University Hospital in Glasgow. A research and development grant of £4.5million has been provided by Scottish Enterprise to the firm to work in collaboration with the NHS and university researchers. BioClavis is a spin-out from molecular profiling company BioSpyder. The grant money...
The UK Government have chosen the University of Glasgow to lead on the Science and Innovation Audit of Precision Medicine Innovation in Scotland. The audit will help to identify opportunities for investment and growth by mapping Scotland’s research, innovation and infrastructure strengths in precision medicine. The aim is to position Scotland as one of the best places to develop precision medicine and build on international...
Following the hugely successful launch of the inaugural Life and Chemical Sciences Leadership Master Class Programme in March 2017, applications are now being taken for the 2018 programme. The focus of this programme is to enhance the development of a leadership pipeline, from within Scotland, to ensure that the ambitious growth targets of both life and chemical science sectors are realised. Next year’s programme,...
NuCana, an Edinburgh-based medical firm has raised almost £75 million by floating on the stock market. NuCana develops techniques to boost the effectiveness of chemotherapy. The funds will be used to further clinical trials and expand the business in Edinburgh creating more jobs in the area. To read the full article, click here.
A global group of laboratories present in more than 40 countries has today unveiled a new facility in Livingston, set to be one of the largest of its kind in the UK, and after investment of £4 million. Bioanalytical testing specialist Eurofins Scientific has revealed the pharmaceutical chemistry, microbiology and water microbiology site after moving from Newbridge. It said the move provides greater capacity for...
Leaders in gene control, Synpromics have announced their new research partnership with Solid Biosciences LLC. The partnership will focus on research around developing treatment options for Duchenne muscular dystrophy (DMD). DMD is a muscle-wasting disease that is progressive, irreversible and ultimately fatal. Currently there is no cure and unsatisfactory treatments for patients. The research aims to advance Solid Biosciences AAV muscle-directed gene therapy research programme....